Tesamorelin Peptide Before and After: What the Trials Measured
Tesamorelin peptide before and after is usually searched as if a photo pair were the evidence. The controlled record is a pair of measurements, not a pair of pictures. Baseline and follow-up came mostly from adults with HIV-associated lipodystrophy, and the main tool was a CT scan rather than a mirror. Tesamorelin is a synthetic analog of growth hormone-releasing hormone. In a finished prescription product it has one narrow labeled use: reducing excess abdominal fat in that condition. A research-grade vial is not that product, and it is not for human consumption. This page covers what changed between the two time points, and what did not.
What before and after meant in the trials
Before was a baseline visit. Investigators measured visceral adipose tissue on a CT slice around L4 to L5, trunk and limb fat by DXA, waist circumference, body weight, IGF-1, lipids, and glucose. After was the same panel at 26 weeks of once-daily exposure, compared with placebo. The labeled prescription regimen in that program is 2 mg subcutaneously once daily. That figure is a drug-label fact for the approved finished product. It is not a reconstitution guide, and it is not a dose for a research vial. Reported exposure figures are kept separate from outcomes on the tesamorelin dosage page.
A forum sequence is a weak stand-in. Those posts are shorter, uncontrolled, and often combined with diet changes, training, and other compounds. A photograph also cannot see visceral fat, which sits around the organs rather than under the skin. Why that depot, and not pinchable belly fat, was the target is covered on the tesamorelin for belly fat page.
What moved between baseline and week 26
Across the phase 3 program, CT-measured visceral adipose tissue was about 15 percent lower than baseline in the tesamorelin arms at 26 weeks. The placebo arms changed little. Subcutaneous abdominal fat did not fall in proportion. Body weight stayed roughly neutral, so the finding reads as a shift in one fat depot, not as weight loss. Waist circumference declined only modestly, which fits a loss of deep tissue rather than a thick layer under the skin. IGF-1 rose, the expected sign that the GHRH receptor pathway was engaged. Some reports noted a modest triglyceride improvement. Limb fat on DXA did not show a meaningful loss, so the pattern is not generalized fat wasting.
These are group averages from adults with HIV-associated lipodystrophy. They are not a forecast for healthy adults, athletes, or ordinary age-related abdominal fat.
| Measure | Role at baseline | Research-reported change by week 26 |
|---|---|---|
| Visceral adipose tissue (CT, about L4 to L5) | Primary endpoint | About 15% lower than baseline on tesamorelin; little change on placebo |
| Subcutaneous abdominal fat | Secondary | Small change relative to the visceral drop |
| Body weight | Safety and secondary readout | Approximately neutral |
| Waist circumference | Secondary | Modest decline |
| IGF-1 | Pharmacodynamic marker | Increased from baseline |
| Limb fat (DXA) | Secondary | No meaningful loss reported |
| After exposure ended | Extension follow-up | Visceral fat tended to move back toward baseline |
The table lists research-reported outcomes from the HIV lipodystrophy program. They are not dosing advice, and they are not expected results outside that population.
Why a four-week photo does not match the papers
The comparison the trials were built to test was week 26, not week 4. A photo at week 3 or week 6 is not that result. IGF-1 can move sooner than a fat depot, because it is a hormone marker, and an early rise is not proof that fat mass has already changed. How that marker behaves is outlined in what tesamorelin does.
When exposure stopped, extension follow-up showed visceral fat moving back toward baseline. The difference depended on continued exposure. It was not a permanent reset, which is the opposite of how many anecdotal sequences are captioned.
What the comparison did not show
The trials did not show cosmetic spot reduction in people without HIV-associated lipodystrophy. They did not show a lasting change after stopping, or fewer heart attacks and strokes. They did not establish safety or efficacy under 18. In the labeled setting, active malignancy, disrupted pituitary function, and pregnancy are situations where the prescription product is not used. Reported effects include injection-site reactions, joint or muscle aches, swelling in the hands or feet, and tingling in the hands. Those are summarized on the tesamorelin side effects page. How narrow the approval is sits on the FDA status page.
A research vial does not inherit the label result. Purity has to come from a certificate of analysis, not from a before-and-after claim. Suppliers that publish lot testing for laboratory material are listed on the supplier page. That list is a sourcing reference only.
Other GH-axis peptides do not share this dataset
CJC-1295 also targets the GHRH receptor, but it does not have this visceral-fat imaging program. Ipamorelin raises growth hormone through the ghrelin receptor instead. Sharing a downstream hormone is not the same as sharing an endpoint. There is no randomized before-and-after set for a tesamorelin plus ipamorelin blend on CT visceral fat, so expecting the 26-week result from a blend is speculation. Half-life and pulse shape are compared on the tesamorelin versus CJC-1295 page.
For laboratory work only, concentration math belongs on the peptide calculator. The calculator does not turn a research compound into a personal protocol. General handling notes sit with the protocols section.
How to read an anecdotal sequence
A posted sequence is an uncontrolled anecdote. It only maps onto the CT result if scale, lighting, diet, training, and other compounds stayed stable, and if the gap is near 26 weeks. Otherwise the research record remains the group difference on imaging, not the photo.